Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs S&P500 ETF (SPY) Price & Performance

Citius Pharmaceuticals IncTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs S&P500 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while S&P500 ETF trades at $773.19. The key difference: S&P500 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRSPY
Market Cap
$20.01M
Sector
Health
52-Week High
$1.82$773.22
52-Week Low
$0.48$631.99
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

S&P500 ETF

SPY, the SPDR S&P 500 ETF Trust, trades at $772.90 with minimal daily movement (-0.02%). Technical indicators show a bullish trend with moving averages supporting upside momentum, though oscillators signal potential overbought conditions. The ETF maintains its position as the world's largest fund with approximately $676 billion in assets. Recent news highlights the S&P 500 reaching record highs while facing valuation concerns with the Shiller P/E ratio at 42, the highest since the dot-com era.

The ETF's outlook remains positive with institutional targets pointing toward 8,000 levels, though elevated valuations and weak market breadth present near-term risks. Dividend income continues to attract investors with reliable distributions, but fee comparisons with competing funds highlight cost considerations for long-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY